Autologous Bone Marrow Transplants to Hematopoietic Stem Cell Support with Peripheral Blood Stem Cells: A Historical Perspective

Cd, Buckner

doi:10.1089/106161299320244

Cited by 20 publications

(14 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each send-out, from Spring 1996 to Autumn 2004 was chronologically assigned with a unique number (i.e., [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]. In this way, we analyzed any effect of the EQA program on the results of the participants as a function of time.…”

Section: Data Processing and Parameter Classificationmentioning

confidence: 99%

“…Nowadays, many clinical studies have established that transplantation of CD34þ stem cells is a potentially curative therapy for many patients with malignant and nonmalignant haematological diseases (4)(5)(6). Initially, autologous and allogeneic HSC transplants have been performed utilizing bone marrow HSCs (7). In the last decade, increasing numbers of transplantations have been carried out using HSCs from mobilized peripheral blood (PB) or umbilical cord blood.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Flow cytometric CD34+ stem cell enumeration: Lessons from nine years' external quality assessment within the Benelux countries

Levering

Preijers

Wieringen

et al. 2007

Cytometry Part B Clinical

View full text Add to dashboard Cite

Background: A biannual external quality assurance (EQA) scheme for flow cytometric CD34+ haematopoietic stem cell enumeration has been operational in the Benelux countries since 1996. In an evaluation of the results of 16 send-outs, we studied the effects of the methods used on assay outcome and whether or not this exercise was effective in reducing between-laboratory variation.Methods: Data were analyzed using robust multivariate regression. This approach is relatively insensitive to outliers and is used to assess the effect of methodological aspects of CD34+ cell counting on the bias and variability.Results: Five variables were associated with significant bias of absolute CD34+ cell counts: (i) unique laboratory number (ULN), (ii) gating strategy; (iii) CD34 mAb fluorochrome; (iv) type of flow cytometer, and (v) method of sample preparation. In addition, ULN and platform methodology (i.e., single vs. dual) contributed significantly to the variability of this assay. Overall, the variability in results of CD34+ cell enumeration has declined with time; in particular, after a practical workshop in which participants were trained to use the ''single platform ISHAGE protocol.'' Conclusions: Between-laboratory variation in CD34+ cell enumeration can be reduced by standardization of methodologies between centres. Our approach, i.e., EQA with targeted training and feedback in response to reported results, has been successful in reducing the variability of CD34+ cell enumeration between participants. q 2007 Clinical Cytometry Society

show abstract

Section: Data Processing and Parameter Classificationmentioning

confidence: 99%

mentioning

confidence: 99%

Flow cytometric CD34+ stem cell enumeration: Lessons from nine years' external quality assessment within the Benelux countries

Levering

Preijers

Wieringen

et al. 2007

Cytometry Part B Clinical

View full text Add to dashboard Cite

show abstract

“…Stem cells represent an important potential for developing cell-based tissue engineering owing to their capacity of self-renewal and differentiation into multiple cell lineages. The clinical success of hematopoietic stem cells has encouraged further characterization of stem cells derived from various tissues [10,11]. To date, at least 6 different dental stem/progenitor cells have been identified [12], including dental pulp stem cells [13], stem cells from exfoliated deciduous teeth [14], periodontal ligament stem cells [15], stem cells from apical papilla [16,17], dental follicle progenitor cells [18], and recently gingiva-derived mesenchymal stem cells [19].…”

Section: Introductionmentioning

confidence: 99%

Epithelial Cell Rests of Malassez Contain Unique Stem Cell Populations Capable of Undergoing Epithelial–Mesenchymal Transition

Xiong

Mrozik

Gronthos

et al. 2012

Stem Cells and Development

View full text Add to dashboard Cite

“…Over the last 15 years or so, cytokine-mobilized peripheral blood stem cells (PBSC) have largely replaced bone marrow as a source of hematopoietic stem cells (HSCs) in the majority of autologous and (in an increasing proportion) allogeneic PBSC transplants (1,2). The HSCs in marrow and peripheral blood, which are responsible for multilineage engraftment in the transplant setting express the cell surface marker CD34 (3,4).…”

mentioning

confidence: 99%

ISHAGE protocol: Are we doing it correctly?

Whitby

Fletcher

et al. 2011

Cytometry Part B Clinical

View full text Add to dashboard Cite

Background: Flow cytometric CD341 stem cell enumeration is routinely performed to optimize timing of peripheral blood stem cell collections and assess engraftment capability of the apheresis product. While a number of different flow methodologies have been described, the highly standardized ISHAGE protocol is currently the most widely employed, with 204/255 (81%) international participants in the UK NEQAS CD341 stem cell enumeration program indicating their use of this method. Recently, two laboratories were identified as persistent poor performers, a fact attributed to incorrect ISHAGE protocol usage/ setup. This prompted UK NEQAS to question whether other laboratories were making similar errors and, if so, how this might affect individual EQA performance.Methods and Results: In send out 0801, where two stabilized samples were issued, the EQA center surveyed 255 participants with flow analysis data and subsequent results collected. One hundred and ninety-six laboratories returned results with 103 returning dot plots. Eighty-three out of one hundred and three stated that they used the ISHAGE protocol gating strategy but 43% (36/83) were incorrectly setup. Analysis of the data showed those incorrectly using single platform ISHAGE gating strategy were twice as likely to fail an EQA exercise compared to those using the protocol correctly. This failure rate increased two fold when incorrect ISHAGE protocol was used in a dual platform setting.Conclusion: This study suggests a widespread fundamental lack of understanding of the ISHAGE protocol and the need to deploy it correctly, potentially having significant clinical implications and highlights the need to monitor participants rigorously in their deployment of the ISHAGE protocol. It is hoped that once these findings have been disseminated, performance can be improved. V C 2011 International Clinical

show abstract

Autologous Bone Marrow Transplants to Hematopoietic Stem Cell Support with Peripheral Blood Stem Cells: A Historical Perspective

Cited by 20 publications

References 35 publications

Flow cytometric CD34+ stem cell enumeration: Lessons from nine years' external quality assessment within the Benelux countries

Flow cytometric CD34+ stem cell enumeration: Lessons from nine years' external quality assessment within the Benelux countries

Epithelial Cell Rests of Malassez Contain Unique Stem Cell Populations Capable of Undergoing Epithelial–Mesenchymal Transition

ISHAGE protocol: Are we doing it correctly?

Contact Info

Product

Resources

About